Daniel J Kim

Dr. Daniel J Kim

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Canadian Journal of Emergency Medicine
Verified
Journal Article
Closed access
PDF file
DLDavid Lewis
David Lewis
LRLouise Rang
Louise Rang
DKDaniel J Kim
Daniel J Kim
LRLaurie Robichaud
Laurie Robichaud
CKCharisse Kwan
Charisse Kwan
POPaul Olszynski
Paul Olszynski

1 March 2010 in Canadian Journal of Emergency Medicine
Verified
Journal Article
Closed access
PDF file
DKDaniel J Kim
Daniel J Kim
BSBrian Steinhart
Brian Steinhart
Bupropion is a newer generation antidepressant that is commonly used for treatment of depression and for smoking cessation. Seizures are a frequently reported adverse effect of bupropion in therapeutic oral doses; however, there are limited data about the consequences of nasal insufflation of bupropion. We report the case of a patient who presented to the emergency department (ED) with a recent history of generalized tonic–clonic seizures whose etiology was initially a diagnostic mystery. After an initial visit to another ED, the patient presented to our ED later that day with a recurrence of the seizures after crushing and nasally insufflating oral bupropion tablets. We review important implications of this case to emergency medicine, including the potential for abuse of bupropion, the difference between intranasal and oral administration, the changing trends in the etiology of drug-related seizures and the importance of examining the nares in patients with unexplained seizure and delirium.

13 October 2022 in Ultraschall in der Medizin - European Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
RJRobert David Jarman
Robert David Jarman
CMCian McDermott
Cian McDermott
ACAnna Colclough
Anna Colclough
MBMorten Bøtker
Morten Bøtker
LKLars Knudsen
Lars Knudsen
KHKing's College Hospital
King's College Hospital
Aims To evaluate the evidence and produce a summary and recommendations for the most common heart and lung applications of point-of-care ultrasound (PoCUS).Methods We reviewed 10 clinical domains/questions related to common heart and lung applications of PoCUS. Following review of the evidence, a summary and recommendation were produced, including assignment of levels of evidence (LoE) and grading of the recommendation, assessment, development, and evaluation (GRADE). 38 international experts, the expert review group (ERG), were invited to review the evidence presented for each question. A level of agreement of over 75 % was required to progress to the next section. The ERG then reviewed and indicated their level of agreement regarding the summary and recommendation for each question (using a 5-point Likert scale), which was approved if a level of agreement of greater than 75 % was reached. A level of agreement was defined as a summary of “strongly agree” and “agree” on the Likert scale responses.Findings and Recommendations One question achieved a strong consensus for an assigned LoE of 3 and a weak GRADE recommendation (question 1). The remaining 9 questions achieved broad agreement with one assigned an LoE of 4 and weak GRADE recommendation (question 2), three achieving an LoE of 3 with a weak GRADE recommendation (questions 3–5), three achieved an LoE of 3 with a strong GRADE recommendation (questions 6–8), and the remaining two were assigned an LoE of 2 with a strong GRADE recommendation (questions 9 and 10).Conclusion These consensus-derived recommendations should aid clinical practice and highlight areas of further research for PoCUS in acute settings.

9 April 2020 in Canadian Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
DKDaniel J Kim
Daniel J Kim
TJTomislav Jelic
Tomislav Jelic
MWMichael Y. Woo
Michael Y. Woo
CHClaire Heslop
Claire Heslop
POPaul Adam Olszynski
Paul Adam Olszynski
The World Health Organization declared the novel coronavirus disease 2019 (COVID-19) to be a pandemic on March 11, 2020, and, currently, there are over 10,000 confirmed cases in Canada, with this number expected to grow exponentially. There has been widespread interest in the use of point-of-care ultrasound (POCUS) in the management of patients with suspected COVID-19. The CAEP Emergency Ultrasound Committee has developed recommendations on the use of POCUS in these patients, with an emphasis on machine infection control measures.

30 December 2010 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
CFConstantine Frangakis
Constantine Frangakis
JGJean-Francois Geschwind
Jean-Francois Geschwind
DKDaniel J Kim
Daniel J Kim
YCYong Chen
Yong Chen
AKAyman Koteish
Ayman Koteish
CGChristos S. Georgiades
Christos S. Georgiades
Introduction The drop-off risk for patients awaiting liver transplantation for hepatocellular carcinoma (HCC) is 22%. Transplant liver availability is expected to worsen, resulting in longer waiting times and increased drop-off rates. Our aim was to determine whether chemoembolization can decrease this risk. Patients and Methods Eighty-seven consecutive HCC patients listed for liver transplant (Milan criteria) underwent statistical comparability adjustments using the propensity score (Wilcoxon, Fisher’s, and chi-square tests). Forty-three nonchemoembolization patients and 22 chemoembolization patients were comparable for Child-Pugh and Model for End-Stage Liver Disease scores, tumor size and number, alpha fetoprotein (AFP) levels, and cause of cirrhosis. We calculated the risk of dropping off the transplant list by assigning a transplant time to those who dropped off (equal probability with patients who were on the list longer than the patient in question). The significance level was obtained by calculating the simulation distribution of the difference compared with the permutations of chemoembolization versus nonchemoembolization assignment of the patients. Kaplan–Meier estimators (log-rank test) were used to determine survival rates. Results Median follow-up was 187 ± 110 weeks (range 38 to 435, date of diagnosis). The chemoembolization group had an 80% drop-off risk decrease (15% nonchemoembolization versus 3% chemoembolization, p = 0.04). Although survival was better for the chemoembolization group, it did not reach statistical significance. Two-year survival for the nonchemoembolization and chemoembolization group was 57.3% ± 7.1% and 76.0% ± 7.9%, respectively (p = 0.078). Conclusions Chemoembolization appears to result in a significant decrease in the risk of dropping off liver transplant list for patients with HCC and results in a tendency toward longer survival.

14 September 2012 in Academic Emergency Medicine
Verified
Journal Article
Closed access
PDF file
DKDaniel J Kim
Daniel J Kim
JTJonathan Theoret
Jonathan Theoret
MLMichael M. Liao
Michael M. Liao
EHEmily Hopkins
Emily Hopkins
KWKaren Woolfrey
Karen Woolfrey
JKJohn L. Kendall
John L. Kendall